Spruce Biosciences, Inc.
SPRBD
$8.20
-$0.30-3.53%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -75.86% | -80.41% | -25.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -75.86% | -80.41% | -25.64% |
| Cost of Revenue | -100.08% | 5.04% | 93.31% | -51.43% | -43.58% |
| Gross Profit | 100.10% | -30.33% | -152.77% | 42.88% | 47.12% |
| SG&A Expenses | -12.20% | -15.35% | 12.30% | 6.77% | 18.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.88% | -0.98% | 76.29% | -40.17% | -27.83% |
| Operating Income | 73.18% | -14.72% | -115.64% | 31.12% | 28.17% |
| Income Before Tax | 77.49% | -20.78% | -136.77% | 29.81% | 28.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 77.49% | -20.78% | -136.77% | 29.81% | 28.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 77.49% | -20.78% | -136.77% | 29.81% | 28.41% |
| EBIT | 73.18% | -14.72% | -115.64% | 31.12% | 28.17% |
| EBITDA | 73.21% | -14.80% | -115.87% | 31.10% | 28.16% |
| EPS Basic | 79.10% | -12.95% | -132.72% | 30.82% | 29.47% |
| Normalized Basic EPS | 79.10% | -12.95% | -132.72% | 30.82% | 29.47% |
| EPS Diluted | 79.10% | -12.95% | -132.72% | 30.82% | 29.47% |
| Normalized Diluted EPS | 79.10% | -12.95% | -132.72% | 30.82% | 29.47% |
| Average Basic Shares Outstanding | 7.71% | 6.94% | 1.75% | 1.46% | 1.52% |
| Average Diluted Shares Outstanding | 7.71% | 6.94% | 1.75% | 1.46% | 1.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |